Retreatment and AETHERA Training Quiz

True or False: Patients who experience AEs during their last treatment with brentuximab vedotin were allowed to start at the last dose used in the retreatment study

True

False

The key response results for the retreatment study are

ORR (CR+PR) was 88% for HL patients and 60% for sALCL with a median duration of response of 12.3 months for sALCL and 9.2 months for HL

ORR (CR+PR) was 60% for HL patients and 88% for sALCL with a median duration of response of 9.2 months for sALCL and 12.3 months for HL

ORR (CR+PR) was 75% for HL patients and 60% for sALCL with a median duration of response of 10 months for sALCL and 7 months for HL

O ORR (CR+PR) was 60% for HL patients and 75% for sALCL with a median duration of response of months 7 months for sALCL and 10 months for HL

The efficacy evaluable population for the retreatment study included:

20 HL and 8 sALCL

8 HL and 20 sALCL

10 HL and 18 sALCL

18 sALCL and 10 HL

Retreatment and AETHERA Training Quiz

More Quizzes